Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Pharmaceutics · 24.05.2024 · 16 (6) · 708
DOI: 10.3390/pharmaceutics16060708 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 24.05.2024. Verfasst von Lisa Sequeira und 9 weiteren Autor:innen. Beteiligte Einrichtung: CIQUP-IMS-Centro de Investigação em Química da Universidade do Porto, Institute of Molecular Sciences, Department of Chemistry and Biochemistry, Facu…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 300 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This work was funded by FEDER funds through the Operational Programme Competitiveness Factors COMPETE and national funds by the Foundation for Science and Tech…, FCT, MCTES, Fundo Social Europeu (FSE), and UE. L. Sequeira, S. Benfeito, C. Fernandes, FEDER funds through the Operational Programme Competitiveness Factors COMPETE.
Themen: Demenz
Abstract (Originalsprache)
Neurodegenerative diseases (NDs) are a set of progressive, chronic, and incurable diseases characterized by the gradual loss of neurons, culminating in the decline of cognitive and/or motor functions. Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the most common NDs and represent an enormous burden both in terms of human suffering and economic cost. The available therapies for AD and PD only provide symptomatic and palliative relief for a limited period and are unable to modify the diseases’ progression. Over the last decades, research efforts have been focused on developing new pharmacological treatments for these NDs. However, to date, no breakthrough treatment has been discovered. Hence, the development of disease-modifying drugs able to halt or reverse the progression of NDs remains an unmet clinical need. This review summarizes the major hallmarks of AD and PD and the drugs available for pharmacological treatment. It also sheds light on potential directions that can be pursued to develop new, disease-modifying drugs to treat AD and PD, describing as representative examples some advances in the development of drug candidates targeting oxidative stress and adenosine A2A receptors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CIQUP-IMS-Centro de Investigação em Química da Universidade do Porto, Institute of Molecular Sciences, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, R. Campo Alegre s/n, 4169-007 Po…
ORCID-Profile: Sofia Benfeito, Joana Peixoto, Catarina Alves, Fernanda Borges, Daniel Chavarria
Förderung
- This work was funded by FEDER funds through the Operational Programme Competitiveness Factors COMPETE and national funds by the Foundation for Science and Tech…
- FCT, MCTES, Fundo Social Europeu (FSE), and UE. L. Sequeira, S. Benfeito, C. Fernandes
- FEDER funds through the Operational Programme Competitiveness Factors COMPETE
- Foundation for Science and Technology (FCT)
- FCT, MCTES, Fundo Social Europeu (FSE), and UE
- FCT and FEDER/COMPETE
Zitieren
APA
Sequeira, L., Benfeito, S., Fernandes, C., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Gaspar, A., Borges, F., & Chavarria, D. (2024). Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?. Pharmaceutics, 16(6), 708. https://doi.org/10.3390/pharmaceutics16060708
Vancouver
Sequeira L, Benfeito S, Fernandes C, Lima I, Peixoto J, Alves C, et al. Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?. Pharmaceutics. 2024;16(6):708. doi:10.3390/pharmaceutics16060708
BibTeX
@article{Sequeira2024,
author = {Sequeira, Lisa and Benfeito, Sofia and Fernandes, Carlos and Lima, Inês and Peixoto, Joana and Alves, Catarina and Machado, Cláudia Sofia and Gaspar, Alexandra and Borges, Fernanda and Chavarria, Daniel},
title = {Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {6},
pages = {708},
doi = {10.3390/pharmaceutics16060708}
}
EUVIMED